Literature DB >> 12415247

Hepatitis C therapeutics: current status and emerging strategies.

Seng-Lai Tan1, Arnim Pause, Yuguang Shi, Nahum Sonenberg.   

Abstract

Chronic infection with hepatitis C virus (HCV) is an emerging global epidemic. The development of effective HCV antiviral therapeutics continues to be a daunting challenge owing to the absence of adequate animal models and tissue-culture systems for analysis and propagation of the virus. Despite these obstacles, inhibitors of the replicative elements of HCV, immune modulators and non-specific hepatoprotective agents are being pursued and exciting progress has been made. Successful therapeutic intervention of HCV will probably require combination approaches and new approaches, including host drug discovery targets.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12415247     DOI: 10.1038/nrd937

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN: 1474-1776            Impact factor:   84.694


  48 in total

1.  The nonstructural protein 3 protease/helicase requires an intact protease domain to unwind duplex RNA efficiently.

Authors:  David N Frick; Ryan S Rypma; Angela M I Lam; Baohua Gu
Journal:  J Biol Chem       Date:  2003-10-29       Impact factor: 5.157

2.  Identification of CED-3 substrates by a yeast-based screening method.

Authors:  Sung Yun Kim; Marcela Valencia; Eui Seung Lee; Daeho Park; Myungsok Oh; Ding Xue; Woo Jin Park
Journal:  Mol Biotechnol       Date:  2004-05       Impact factor: 2.695

3.  NS3 helicase actively separates RNA strands and senses sequence barriers ahead of the opening fork.

Authors:  Wei Cheng; Sophie Dumont; Ignacio Tinoco; Carlos Bustamante
Journal:  Proc Natl Acad Sci U S A       Date:  2007-08-20       Impact factor: 11.205

Review 4.  Understanding the interaction of hepatitis C virus with host DEAD-box RNA helicases.

Authors:  Megha Haridas Upadya; Jude Juventus Aweya; Yee-Joo Tan
Journal:  World J Gastroenterol       Date:  2014-03-21       Impact factor: 5.742

5.  Anti-hepatitis C virus activity of novel beta-d-2'-C-methyl-4'-azido pyrimidine nucleoside phosphoramidate prodrugs.

Authors:  Ramu Rondla; Steven J Coats; Tamara R McBrayer; Jason Grier; Melissa Johns; Phillip M Tharnish; Tony Whitaker; Longhu Zhou; Raymond F Schinazi
Journal:  Antivir Chem Chemother       Date:  2009-10-19

6.  3.0T 31P MR spectroscopy in assessment of response to antiviral therapy for chronic hepatitis C.

Authors:  Chun-Yu Zhang; Qian Zhang; Hui-Mao Zhang; Hai-Shan Yang
Journal:  World J Gastroenterol       Date:  2014-02-28       Impact factor: 5.742

7.  Synthesis and anti-hepatitis B virus and anti-hepatitis C virus activities of 7-deazaneplanocin A analogues in vitro.

Authors:  Hyo-Joong Kim; Ashoke Sharon; Chandralata Bal; Jianing Wang; Madhan Allu; Zhuhui Huang; Michael G Murray; Leda Bassit; Raymond F Schinazi; Brent Korba; Chung K Chu
Journal:  J Med Chem       Date:  2009-01-08       Impact factor: 7.446

8.  A virocidal amphipathic {alpha}-helical peptide that inhibits hepatitis C virus infection in vitro.

Authors:  Guofeng Cheng; Ana Montero; Pablo Gastaminza; Christina Whitten-Bauer; Stefan F Wieland; Masanori Isogawa; Brenda Fredericksen; Suganya Selvarajah; Philippe A Gallay; M Reza Ghadiri; Francis V Chisari
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-19       Impact factor: 11.205

9.  Disruption of hepatitis C virus RNA replication through inhibition of host protein geranylgeranylation.

Authors:  Jin Ye; Chunfu Wang; Rhea Sumpter; Michael S Brown; Joseph L Goldstein; Michael Gale
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-10       Impact factor: 11.205

10.  Advances in antisense oligonucleotide development for target identification, validation, and as novel therapeutics.

Authors:  Moizza Mansoor; Alirio J Melendez
Journal:  Gene Regul Syst Bio       Date:  2008-09-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.